Currently out of the existing stock ratings of Mason Carrico, 34 are a BUY (89.47%), 4 are a HOLD (10.53%).

Mason Carrico

Work Performance Price Targets & Ratings Chart

Analyst Mason Carrico works at STEPHENS with a stock forecast success ratio of 36.11% fulfilled within 51.58 days on average.

Mason Carrico’s has documented 75 price targets and ratings displayed on 12 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on CDNA, Caredx at 13-May-2024.

Wall Street Analyst Mason Carrico

Analyst best performing recommendations are on OCX (ONCOCYTE CORP).
The best stock recommendation documented was for OCX (ONCOCYTE CORP) at 5/24/2022. The price target of $25 was fulfilled within 16 days with a profit of $5.31 (26.97%) receiving and performance score of 16.86.

Average potential price target upside

CSTL Castle Biosciences DMTK DermTech GH Guardant Health OCX OncoCyte Corp VCYT Veracyte AKYA Akoya Biosciences MYGN Myriad Genetics CDNA Caredx NEO NeoGenomics TXG 10X Genomics ILMN Illumina NTRA Natera

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

37

$12.76 (52.64%)

32

2 months 17 days ago

3/9 (33.33%)

$17.06 (85.56%)

29

Buy

28

$3.76 (15.51%)

37

2 months 17 days ago

2/5 (40%)

$8.06 (40.42%)

22

Buy

35

$10.76 (44.39%)

40

4 months 29 days ago

1/5 (20%)

$13.92 (66.03%)

70

Buy

32

$7.76 (32.01%)

32

10 months 11 days ago

0/5 (0%)

$11.7 (57.64%)

Buy

30

$5.76 (23.76%)

35

11 months 3 days ago

3/4 (75%)

$16.6 (123.88%)

44

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Mason Carrico is most bullish on?

Potential upside of $58.93 has been obtained for ILMN (ILLUMINA)

Which stock is Mason Carrico is most reserved on?

Potential downside of -$28.46 has been obtained for NTRA (NATERA)

What Year was the first public recommendation made by Mason Carrico?

On 2022

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?